| Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 17822459 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate [(11)C]-choline positron-emission tomography (PET)/computed tomography (CT) for detecting clinical recurrence after primary treatment for prostate cancer. PATIENTS AND METHODS: In all, 50 patients with prostate cancer who had had initial therapy (radical prostatectomy in 40, external beam radiation in three and interstitial brachytherapy in seven) had PET/CT using [(11)C]-choline in the presence of an increased or increasing prostate-specific antigen (PSA) level. The mean (range) time to biochemical progression was 22 (2-136) months. Current PSA levels were determined in all patients at the time of examination. The results were correlated with the histopathology reports after targeted biopsy or surgery, and with the clinical follow-up. RESULTS: The mean (median, range) PSA level in patients with positive PET/CT was 3.62 (2.42, 0.5-13.1) ng/mL, and that in patients with a negative scan was 0.90 (0.95, 0.41-1.40) ng/mL. PET/CT was positive in seven of 13 patients with a PSA level of <1.5 ng/mL, and histology was positive in this group in nine. In 17 patients with PSA levels of 1.5-2.5 ng/mL PET/CT was positive in all and the histology was positive in 13; in 11 men with a PSA level of 2.5-5 ng/mL PET/CT was positive in all 11 and the histology was positive in 10; in nine men with PSA levels of >5 ng/mL PET/CT identified all as positive and the histology was positive in eight. The sensitivity at a PSA level of <2.5 ng/mL of PET/CT for detecting recurrence was 91% (95% confidence interval, 71-99%) with a specificity of 50% (16-84)%. CONCLUSION: [(11)C]-choline PET/CT seems to be useful for re-staging prostate cancer after curative therapy and with increasing PSA levels; this was verified by histological examination. We recommend this method at PSA levels of <2.5 ng/mL. |
| | |
Authors:
|
Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend |
Related Documents
:
|
10849539 - Imaging of malignant cervical lymphadenopathy. 16319609 - Diagnostic utility of positron emission tomography-computed tomography for predicting m... 11973489 - Reproducibility and clinical value of 18f-fluorodeoxyglucose positron emission tomograp... 10082249 - 18fluoro-2-deoxyglucose (18fdg) pet scan of the brain in type iv 3-methylglutaconic aci... 19890899 - Noninvasive imaging surrogate of angiogenesis in osteosarcoma. 16724209 - Evaluation of the impact of addition of pet to ct and mr scanning in the staging of pat... 6380719 - Digital angiography in the diagnosis of congenital heart disease. 3780769 - Dynamic imaging of the compliant perfusion of the lungs. 3464789 - Evaluation of supra- and infratentorial brain atrophy by computerised tomography in spi... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article |
Journal Detail:
|
Title: BJU international Volume: 100 ISSN: 1464-4096 ISO Abbreviation: BJU Int. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-09-07 Completed Date: 2007-11-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100886721 Medline TA: BJU Int Country: England |
Other Details:
|
Languages: eng Pagination: 786-93 Citation Subset: IM |
Affiliation:
|
Department of Urology, University of Ulm, Ulm, Germany. ludwig.rinnab@uniklinik-ulm.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Choline / diagnostic use Follow-Up Studies Humans Male Middle Aged Neoplasm Recurrence, Local / radionuclide imaging* Neoplasm Staging Prognosis Prostate-Specific Antigen / blood Prostatectomy / methods Prostatic Neoplasms / radionuclide imaging*, therapy Radiopharmaceuticals / diagnostic use Sensitivity and Specificity Tomography, Emission-Computed / standards* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 62-49-7/Choline; EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
Next Document: Cryoablation of small renal masses: assessment of the outcome at one institution.